Publicaciones en colaboración con investigadores/as de Instituto Valenciano de Oncologia (12)

2024

  1. Efficacy and safety of cemiplimab in the treatment of advanced cutaneous squamous cell carcinoma: A multicentre real-world retrospective study from Spain and systematic review of the published data

    Journal of the European Academy of Dermatology and Venereology

2023

  1. Sonidegib as a Locally Advanced Basal Cell Carcinoma Therapy in Real-life Clinical Setting: A National Multicentre Study

    Actas Dermo-Sifiliograficas, Vol. 114, Núm. 7, pp. T565-T571

2022

  1. Activity and safety of topical pimecrolimus in patients with early stage mycosis fungoides (PimTo-MF): a single-arm, multicentre, phase 2 trial

    The Lancet Haematology, Vol. 9, Núm. 6, pp. e425-e433

2019

  1. MC1R variants in childhood and adolescent melanoma: a retrospective pooled analysis of a multicentre cohort

    The Lancet Child and Adolescent Health, Vol. 3, Núm. 5, pp. 332-342

2017

  1. Primary Breast Lymphoma: Analysis of 55 Cases of the Spanish Lymphoma Oncology Group

    Clinical Lymphoma, Myeloma and Leukemia, Vol. 17, Núm. 3, pp. 186-191

2015

  1. MC1R gene variants and non-melanoma skin cancer: A pooled-analysis from the M-SKIP project

    British Journal of Cancer, Vol. 113, Núm. 2, pp. 354-363

  2. MC1R variants increased the risk of sporadic cutaneous melanoma in darker-pigmented Caucasians: A pooled-analysis from the M-SKIP project

    International Journal of Cancer, Vol. 136, Núm. 3, pp. 618-631

2013

  1. Registro nacional de melanoma cutáneo. Características del tumor en el momento del diagnóstico: 15 años de experiencia

    Actas Dermo-Sifiliograficas, Vol. 104, Núm. 9, pp. 789-799

2012

  1. First-Line XELOX plus bevacizumab followed by XELOX plus bevacizumab or single-agent bevacizumab as maintenance therapy in patients with metastatic colorectal cancer: The phase III MACRO TTD study

    Onkologie, Vol. 6, Núm. 2, pp. 96-103

  2. First-line XELOX plus bevacizumab followed by XELOX plus bevacizumab or single-agent bevacizumab as maintenance therapy in patients with metastatic colorectal cancer: The phase III MACRO TTD study

    Oncologist, Vol. 17, Núm. 1, pp. 15-25

  3. Melanocortin-1 receptor, skin cancer and phenotypic characteristics (M-SKIP) project: Study design and methods for pooling results of genetic epidemiological studies

    BMC Medical Research Methodology, Vol. 12

  4. Role of Kras Status in Patients with Metastatic Colorectal Cancer Receiving First-Line Chemotherapy plus Bevacizumab: A TTD Group Cooperative Study

    PLoS ONE, Vol. 7, Núm. 10